The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.

In one aspect, the disclosure relates to relates to compositions, devices, and processes for drug delivery to an eye. The disclosed drug delivery compositions comprise a particle having a core component comprising a first polymer and a therapeutic agent, and a shell layer surrounding the core component comprising a second polymer. In a further aspect, the present disclosure relates to methods of treating an ophthalmological disease or disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

A composition including albumin for use in the treatment of Amyotrophic Lateral Sclerosis (ALS), wherein the composition is administrated to the patient by plasma exchange using a volume of the composition equivalent to approximately 100% of the volume of plasma withdrawn from the patient, and with a frequency of twice a week the first 3 weeks and once a week for the following 21 weeks, for a total period of 24 weeks.

Various examples of systems and methods for making microspheres, microparticles, and emulsions are provided. In one example, a system and method for forming microspheres comprises: pumping a dispersed phase liquid and a continuous phase liquid into a levitating magnetic impeller pump to subject the dispersed phase liquid and continuous phase liquid to a high shear environment within the impeller pump's pump chamber. In another example, a system and method for forming an emulsion comprises: pumping a dispersed phase liquid and an inner aqueous phase liquid into a levitating magnetic impeller pump to subject the dispersed phase and the inner aqueous phase to a high shear environment within the impeller pump's pump chamber.

Disclosed herein are oxygen transporting formulations, in particular those composed of hemoglobin-based nanoparticles, and their use and process of manufacture. These formulations are more uniform and monodisperse than prior hemoglobin-based oxygen carriers, such as polymeric hemoglobin. In addition, these formulations provide higher hemoglobin encapsulation efficiencies and higher hemoglobin content that hemoglobin-containing vesicles.

A preparation method of a human albumin-containing medical product comprises controlling a content of long-chain fatty acids in the medical product and adding poloxamer to the medical product. The long-chain fatty acid is one or more selected from myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid and arachidonic acid, and a molar ratio of the long-chain fatty acids and human albumin is 0.2-3.0. A content of the poloxamer is 10-500 μg/g of human albumin. The human albumin-containing medical product prepared by the method has improved stability and does not contain particle of over 30 nm in diameter is formed from aggregation and/or fibrillation of human albumin.

The invention relates to an anti-thrombotic molecule having both anti-platelet and anti-coagulant (APAC) activity and, in particular, its use as a medicament to prevent and/or treat heparin-induced thrombocytopenia (HIT) type I or II; and/or heparin-induced thrombocytopenia and thrombosis (HITT); and/or heparin-independent thrombocytopenia autoimmune HIT (aHIT); and/or vaccine-induced thrombocytopenia and thrombosis (VITT). The invention has use in both the medical and veterinary industries.

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

The present invention relates to methods of treating cancer with a combination of extended-PK IL-2 and one or more therapeutic agents, such as a therapeutic antibody. The methods of the invention are applicable across any type of cancer.

The present invention provides a group of polypeptides and a complex formed by the polypeptides and human serum albumin, a method for improving the solubility of the group of polypeptides in a salt solution by combining the polypeptides with human serum albumin, a method for preparing the complex formed by the group of polypeptides and human serum albumin, and an application of the group of polypeptides and the complex formed by the polypeptides and human serum albumin in the preparation of drugs for suppressing tumor metastasis and treating leukemia.